

25 February 2022

Ms Michaels
The Society of Hospital Pharmacists of Australia (SHPA)

RE. UPDATED SUPPLY NOTIFICATION FOR YERVOY (IPILIMUMAB) AND OPDIVO (NIVOLUMAB)

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to provide you a further update regarding Yervoy (Ipilimumab) and Opdivo (Nivolumab) supply shortages and resolutions as outlined below:

Product Stock Status, 25 February 2022

BMS Code	BMS Product	Stock Status	Anticipated Resolution
1279684	YERVOY SINJ 200MG (1VLX40ML) AU/NZ	Confirmed out of stock	Week commencing 14 March 2022
1279683	YERVOY SINJ 50MG (1VLX10ML) AU/NZ	In Stock. Low Stock Levels	Week commencing 14 March 2022
BMS Code	BMS Product	Stock Status	Anticipated Resolution
1394080	OPDIVO SINJ 40MG (1VLX4ML) AU	In Stock. Low Stock Levels	Week commencing 23 May 2022
1394152	OPDIVO SINJ 100MG (1VLX10ML) AU	In Stock	Stock Shortage Resolved

BMS knows the importance of a steady and reliable supply of critical medicines for patients and has been working tirelessly to accelerate supply shipments in order to minimize the impact to patients. Key changes since our last communication dated February 11 include:

- Resolution of the anticipated stock shortage for the Opdivo (Nivolumab) 100mg/10mL vial.
- Change from anticipated out of stock to a period of low stock for the Opdivo (Nivolumab) 40mg/4mL vial and Yervoy (Ipilimumab) 50mg/10mL vial.

During periods of low stock BMS will continue to manage and monitor all orders to ensure equity of access for Australian patients and to prevent out of stock periods.

BMS continues to update the Therapeutics Goods Administration (TGA) of any changes to current or anticipated supply shortages. As this is a dynamic situation please also refer to the TGA Medicine Shortage Database for up-to-date information <https://apps.tga.gov.au/Prod/msi/search?shortagetype=All>.

If you have any questions relating to the shortage, please contact the BMS Medical Information Department at 1800 067 567 (option 2) or via email at: medinfo.australia@bms.com.

Yours sincerely,

Kate Church

Bristol-Myers Squibb Australia

Kate Church PhD

Associate Medical Director
Medical Department Australia

Level 2
4 Nexus Court
Mulgrave Vic 3170